Bedrijfsoverzicht
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical entity dedicated to the end-to-end process of discovering, developing, and commercializing novel medicines and underlying technologies. The company operates within the broader Healthcare sector, specifically specializing in the Biotechnology industry, where it pursues high-risk, high-reward scientific advancements rather than established consumer goods. As of the latest reporting period, the organization maintains a substantial market capitalization of $20.19 billion, supported by an annualized revenue run rate of $13.31 million and a workforce comprising 750 employees. The disparity between the $20.19 billion market cap and the $13.31 million revenue figure indicates that the company's valuation is driven almost exclusively by the potential value of its clinical product pipeline and intangible assets, such as the fully human monoclonal antibody IMVT-1402, rather than current cash flows from sales. This structural valuation suggests the market prices the company based on future commercialization expectations and regulatory milestones rather than historical financial performance or immediate profitability.
Financiële gezondheid
The company reports a trailing twelve-month revenue of $13.31 million, while simultaneously posting a net income loss of $809,240,000 and an EBITDA deficit of $1,264,381,952. The significant gap between the modest revenue of $13.31 million and the massive net income loss of $809,240,000 reveals a cost structure heavily weighted toward research and development expenditures, clinical trial costs, and general administrative expenses that far exceed current sales generation. Free cash flow stands at -$334,342,944, indicating a heavy burn rate that necessitates continuous capital raising or cash reserve deployment to fund ongoing operations and scientific discovery. The company holds a robust cash balance of $4.53 billion, which starkly contrasts with its total debt obligation of $108.94 million, suggesting a liquidity position dominated by liquid assets available for strategic deployment. Despite the overwhelming cash reserves, the debt-to-equity ratio is calculated at 2.19, implying a leveraged balance sheet structure relative to shareholders' equity, although the absolute debt load remains small compared to available cash. Operating liquidity is exceptionally high, evidenced by a current ratio of 30.66, which signifies an abundance of current assets relative to current liabilities and provides a wide safety margin against short-term obligations. Return on Equity is -19.1% and Return on Assets is -14.5%, metrics that reflect the dilutive impact of operating losses on the existing equity base and asset productivity during the clinical development phase.
Waarderingsbeoordeling
Valuation multiples for the company present a complex picture due to the lack of positive earnings, with a Trailing P/E ratio listed as N/A and a Forward P/E of -24.34. The negative forward P/E ratio of -24.34, coupled with the absence of a trailing P/E, implies that the market expects future earnings to remain negative or that earnings have not yet stabilized to support a traditional multiple based on current profitability. The price-to-book ratio stands at 4.69, indicating that the market values the company at a significant premium of 469% over its tangible book value, likely reflecting the high value assigned to its intellectual property and clinical assets. Alternative valuation metrics further highlight this premium, with a price-to-sales ratio of 1516.90 and an EV/EBITDA of -13.03, suggesting that valuation is decoupled from traditional sales and earnings generation models. Regarding trading range, the stock has a 52-week high of $30.33 and a 52-week low of $9.87; without a specific current price provided in the source data, the valuation context relies on these historical bounds which define the maximum volatility experienced over the past year. The company exhibits a beta of 1.21, meaning its stock price volatility is expected to be 21% higher than the broader market, reflecting the inherent risks associated with clinical-stage biotechnology development.
Growth & Income
The company is currently experiencing a contraction in top-line performance, with revenue growth year-over-year at -77.8%, while earnings growth is listed as N/A due to the absence of positive earnings in the prior period. Since the company is not generating positive earnings, the comparison between revenue growth and earnings growth is not applicable in a traditional sense, as the negative earnings growth is a direct mathematical consequence of the substantial R&D spending rather than a divergence from revenue expansion. As a non-dividend payer, the company does not distribute income to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow is retained within the organization. This retention strategy aligns with the standard operational model for clinical-stage biopharmaceutical firms that prioritize reinvesting capital into their drug discovery programs and clinical trials over returning cash to investors. Consequently, the overall growth and income profile is defined by a high cash burn rate, a lack of current income distribution, and a reliance on future clinical successes to potentially reverse the current revenue contraction and achieve profitability.